Ramadaan and Diabetes : South Africa
|
|
- Silvia Blair
- 6 years ago
- Views:
Transcription
1 Ramadaan and Diabetes : South Africa M.A.K. Omar Dept. of Diabetes and Endocrinology Nelson R Mandela School of Medicine University of KwaZulu Natal South Africa
2 Conflict of Interest Statement - Nil Acted as a consultant for and/or received support from: Astra-Zeneca, BMS,Boehringer-Ingelheim, Eli Lilly, MSD, Medtronic, Merck, Novartis, Novo Nordisk, Pfizer,Roche,SanofiAventis,Servier
3 Section 1: Brief Introduction to Ramadan
4 The Holy Quran, Surah Al Baqarah 2:185 Ramadan is the (month) in which was sent down the Quran, as a guide to mankind, also clear (Signs) for guidance and judgment (between right and wrong). So every one of you who is present (at his home) during that month should spend it in fasting, but if any one is ill, or on a journey, the prescribed period (should be made up) by days later. Allah intends every facility for you; He does not want to put to difficulties. (He wants you) to complete the prescribed period, and to glorify Him in that He has guided you; and perchance ye shall be grateful.
5 Ramadan: Background Ramadan is a holy month in the Islamic calendar Healthy Muslims are obliged to abstain from all food, drink, and oral medications from dawn to sunset throughout the month Those exempt from fasting include children below the age of 12, individuals with illness, travelers, and women who are menstruating, pregnant, or nursing There is a significant change in meal pattern, sleep/wake cycle and spiritual and social activities. Ramadan is the ninth month of the Islamic lunar calendar Duration varies between 29 and 30 days Each year it occurs approximately 10 days earlier Every 9 years it occurs in a different season The hours spent fasting can range from only a few hours to more than 20 hours depending on geographical location and season Most people eat 2 meals a day during Ramadan Suhur (meal before dawn) and Iftar (meal after sunset)
6 Section 2: Physiological Impact of Fasting
7 Pathophysiology of Postprandial State In non-diabetic individuals: Eating stimulates insulin secretion, which promotes storage of glucose in liver and muscle as glycogen Insulin secretion suppresses glucagon secretion Increased insulin concentrations and suppressed glucagon stop hepatic glucose production In diabetic individuals: Insulin secretion is perturbed; after eating, glucagon levels remain high after a meal and glucose released by the liver continues to enter circulation, resulting in hyperglycemia Al-Arouj et al. Diabetes Care 2010;33(8): Aronoff et al. Diabetes Spectrum 2004;17(3):
8 Section 3: Clinical Implications of Fasting
9 Potential Complications of Fasting Hypoglycemia Hyperglycemia Diabetes Keto-acidosis Dehydration Thrombosis Changes in weight During Ramadan
10 Complications of Fasting: Hypoglycemia Risk increases when you decrease food intake 1 There is an increased risk of severe hypoglycemia in individuals with diabetes who fast during Ramadan fold increase in type 1 diabetes patients 7.5-fold increase in type 2 diabetes patients Patients who do not change dosages of oral medications or insulin and who have significant lifestyle changes during Ramadan are more likely to have hypoglycemia 2 1. DCCT Research Group. N Engl J Med 1993;329(14): Salti et al. Diabetes Care 2004;27(10):
11 Complications of Fasting: Hyperglycemia Several studies have shown mixed results with regard to loss of glycemic control in patients with diabetes who fast during Ramadan 1-5 The incidence of severe hyperglycemia has been shown to increase 6 3-fold in type 1 diabetes patients fasting during Ramadan 5-fold in type 2 diabetes patients fasting during Ramadan Patients with an increase in food and/or sugar intake have significantly higher rates of severe hyperglycemia 6 1. Miller et al. Arch Intern Med. 2001;161: UKPDS Group. Lancet 1998;352: Beckman et al. JAMA. 2002;287: Akhan et al. Acta Neurol Scand. 2000;101: Alghadyan et al. Ann Ophthalmol. 1993;25: Salti et al. Diabetes Care. 2004;27(10):
12 Potential Complications of Fasting: Weight Change The effect of the fasting period of Ramadan on weight is not definitive Studies have shown weight gain, loss, and no change in patients fasting during Ramadan 1-5 Variability in weight changes may be attributed to local traditions and food quality 5 1. Sari et al. Endocr Res 2004;30(2): Uysal et al. Diabetes Care 1998;21(11): Mafauzy et al. Med J Malaysia 1990;45(1): Khatib et al. Saudi Med J 2004;25(12): Rashed AH. BMJ 1992;304(6826):521-2.
13 Section 4: Epidemiology of Fasting During Ramadan
14 EPIDIAR: A Population-Based Study of Diabetes and Its Characteristics During the Fasting Month of Ramadan in 13 Countries
15 EPIDIAR: Fasting Statistics Patients fasting 15 days 42.8% of type 1 diabetes patients 78.7% of type 2 diabetes patients Inter-country differences in patients fasting 15 days Range: 9.4% in Morocco to 71.6% in Saudi Arabia among type 1 diabetes patients Range: 57.8% in Turkey to 89.8% in Malaysia and Bangladesh among type 2 diabetes patients Average number of fasting days 23 days among type 1 diabetes patients 27 days among type 2 diabetes patients Salti et al. Diabetes Care 2004;27(10):
16 EPIDIAR: Change in Weight Type 1 Diabetes N=1070 Type 2 Diabetes N=11,173 Weight changes, n (%) No change Gain Loss 562 (62.5) 161 (17.9) 176 (19.6) 5286 (54.1) 1861 (19.1) 2628 (26.9) Value of weight change, kg Overall population Patients who fasted at least 1 day Patients who reported weight gain Patients who reported weight loss 332 (0.12±3.79) 235 (-0.51±3.23) 159 (3.24±2.71) 173 (-2.74±1.92) 4367 (-0.25±3.25) 4152 (-0.32±3.08) 1811 (2.78±2.49) 2556 (2.39±1.61) Data are n (%) or n (means ± SD). Salti et al. Diabetes Care 2004;27(10):
17 EPIDIAR: Change in Medication Insulin dose, n (%) Increased Decreased Maintained Stopped OAM dose, n (%) Increased Decreased Maintained Stopped OAM = oral antihyperglycemic medication. Type 1 Diabetes N= (10.7) 237 (24.0) 637 (64.5) 8 (0.8) 5 (5.3) 14 (14.9) 74 (78.7) 1 (1.1) Type 2 Diabetes N=11, (8.2) 452 (24.7) 1174 (64.1) 55 (3.0) 415 (4.4) 1779 (18.8) 7085 (74.8) 197 (2.1) Salti et al. Diabetes Care 2004;27(10):
18 EPIDIAR: Conclusions Prevalence estimates for diabetics fasting during Ramadan were 43% for type 1 diabetes and 86% for type 2 diabetes patients Only 1 in 4 patients changed oral antihyperglycemic medication dosage during Ramadan Only 1 in 3 patients changed insulin dosage during Ramadan Severe hypoglycemia and severe hyperglycemia were more frequent during Ramadan than in the preceding year Salti et al. Diabetes Care 2004;27(10):
19 Section 5: Studies of the Effects of Available Therapy on Glycemic Control in Ramadan
20 Dietary Habits During Ramadan Daily caloric and carbohydrate intake has been shown to decrease among diabetic patients during Ramadan 1 65% of daily caloric intake occurs during Iftar (after sunset meal) 2 Considerable quantities of traditionally sweet and carbohydrate-rich foods are consumed during nonfasting hours 1 The dietary habits during non-fasting hours increase the risk of hyperglycemia and weight gain in diabetic patients 3 1. Benaji et al. Diabetes Res Clin Pract 2006;73(2): Gharbi et al. East Mediterr Health J 2003;9(1-2): Rashed. BMJ 1992;304(6826):521-2.
21 Oral Antihyperglycemic Medications During Ramadan In patients with well-controlled type 2 diabetes, oral antihyperglycemic medication (OAMs) administered at sunset meal (Iftar) and sunrise meal (Suhur) 1-3 generally: Improve or have no effect on glycemic control Do not increase hypoglycemic episodes Hyperglycemic episodes have been shown in patients who arbitrarily reduce or stop their OAMs 4 1. Mafauzy et al. Med J Malaysia 1990;45(1): Khatib et al. Saudi Med J 2004;25(12): Belkhadir et al. BMJ 1993;307(6899): Benaji et al. Diabetes Res Clin Pract 2006;73(2):
22 Patients, % Nearly 20% of SU-Treated Muslim Patients With Type 2 Diabetes Experienced Symptomatic Hypoglycemia During Ramadan Fasting 1 Incidence of Symptomatic Hypoglycemia During Ramadan in 2009 by Treatment Group Glimepiride Gliclazide Glibenclamide 10 Glipizide Overall 5 0 n=428 n=386 n=535 n=29 n= occurred among the 271 patients who recorded 1 symptomatic hypoglycemic event Most common symptoms reported were: headache (14.5%), sweating (10.2%), tremor (8.5%), and palpitations (7.0%) Mean daily doses of SUs were: 2.8 mg for glimepiride, mg for gliclazide, 10.7 mg for glibenclamide (glyburide), and 6.6 mg for glipizide. SU=sulfonylurea. 1. Aravind SR et al. Curr Med Res Opin. 2011;27(6):
23 Patients, % 6.7% of SU-Treated Muslim Patients With Type 2 Diabetes Experienced Severe Hypoglycemia During Ramadan Fasting 1 Incidence of Severe Hypoglycemia During Ramadan in 2009 by Treatment Group Glimepiride Gliclazide Glibenclamide Glipizide Overall 2 0 n=428 n=386 n=535 n=29 n=1378 No marked differences in the incidence of severe hypoglycemia between treatment groups The incidence of severe hypoglycemia requiring medical assistance was 3.7% for the entire patient cohort 1.2% of patients experienced a serious hypoglycemia-related complications during Ramadan 1. Aravind SR et al. Curr Med Res Opin. 2011;27(6):
24 Patients, % Switching to Sitagliptin Treatment Was Associated With a Significantly Lower Incidence of Symptomatic Hypoglycemia Compared With Remaining on Sulfonylurea Treatment 1 Primary End Point (APaT Population): Incidence of Symptomatic Hypoglycemia (Proportion of Patients With 1 Events) RRR (95% CI) = 0.51 (0.34, 0.75); P < Sitagliptin 100 mg qd ± metformin (n=507) SU ± metformin (n=514) symptomatic hypoglycemic events were reported by 68 patients in the SU group compared with 128 events in 34 patients for the sitagliptin group Most common symptoms were headache, sweating, dizziness, hunger, and tremor Mean doses of SUs were: 3.5 mg in the morning and 3.1 mg in the evening for glimepiride; 71.9 mg and 89.0 mg for gliclazide; and 6.1 mg and 5.9 mg for glibenclamide (glyburide). APaT=all patients as treated; CI=confidence interval; qd=once daily; RRR=relative risk ratio; SU=sulfonylurea. 1. Current Medical Research & Opinion Vol. 28, No. 8, 2012,
25 Vildagliptine During Ramadan study 52 patients preparing for Ramadan Currently poorly controlled (HbA 1 c >8.5%) Minimum Metformin 2g/day Randomised to receive Gliclazide 160mg bd Vildagliptin 50mg bd Results: Hypos were more common in gliclazide group 61.5 vs 7.7% (p < 0.001) One Severe hypo in gliclazide arm HbA1c Similar reductions Devendra et al Int J Clin Pract, 2009
26 Patients treated with insulin. Judicious use of intermediate- or long acting insulin preparations plus a short acting insulin administered before meals. Rapid acting insulin analogs are associated with less PP excursions and less risk of hypoglycaemia Diabet Med 1999;16: Diabetes Res Clin Pract 2003; 59:
27 Insulin Lispro Mix 50 (LM50) vs. Human Insulin 30/70 During Ramadan Enrollment Lead-in Ramadan Human Insulin Mixture 30/70 Human Insulin Mixture 30/70 n=79 Type 2 diabetes patients already taking Human Insulin Mixture 30/70 BID Human Insulin Mixture 30/70 QAM; LM50 QPM Human Insulin Mixture 30/70 QAM; LM50 QPM n= Weeks BID = twice daily; LM50 = 50% insulin lispro protamine suspension; 50% insulin lispro; QAM = once in the morning; QPM = once in the evening. 6 Hui et al. Int J Clin Pract 2010;64(8):
28 Insulin Lispro Mix 50 (LM50) vs. Human Insulin 30/70 During Ramadan: HbA1c LM50 50/50 p= difference in change between groups Hui et al. Int J Clin Pract 2010;64(8):
29 Insulin Lispro Mix 50 (LM50) vs. Human Insulin 30/70 During Ramadan: Frequency of Hypoglycemia LM50 50/50 p=0.36 difference in change between groups Hui et al. Int J Clin Pract 2010;64(8):
30 Pharmacotherapy During Ramadan for Treatment of Type 2 Diabetes Metformin Acarbose Outcomes Associated with Use During Ramadan No data are available for patients fasting for long periods while taking only metformin No data are available for patients fasting for long periods while taking only acarbose 2 Risk of Hypoglycemia During Ramadan Unknown (risk is 0-21% in nonfasting patients) 1 Risk of hypoglycemia is low in non-fasting patients 2 Sulfonylurea (glimiperide) Rapid-acting insulin secretagogue (repaglinide) Switching once daily dose to be taken with Iftar vs. Suhur showed no change in glycemic control or hypoglycemia 3 Improved glycemic control vs. glibenclamide 5 No differences in glycemic control or body weight vs. glimiperide or gliclazide 6 No difference vs. repaglinide during fasting 4 Fewer hypoglycemic events vs. glibenclamide during fasting 6 1. Bolen et al. Ann Intern Med 2007;147(6): Pan et al. Diabet Med 2008;25(4): Glimiperide in Ramadan (GLIRA) Study Group. Diabetes Care 2005;28(2): Anwar et al. Med J Malaysia 2006;61(1): Mafauzy et al. Diabetes Res Clin Pract 2002;58(1): Sari et al. Endocr Res 2004;30(2):
31 Pharmacotherapy During Ramadan for Treatment of Type 2 Diabetes TZDs (pioglitazone) DPP-4 Inhibitors (Vildagliptin, Sitagliptin) Outcomes Associated with Use During Ramadan Improved glucose control with vildagliptin+metformin vs. gliclazide+metformin 2 -- Risk of Hypoglycemia During Ramadan No increase if hypoglycemic events vs. placebo during fasting 1 Reduced incidence of hypoglycemia with vildagliptin+metformin vs. gliclazide+metformin 2 GLP-1 (exenatide) Audit findings suggest no dose adjustments needed during Ramadan, though other agents taken with GLP-1 (such as SUs) may need to be reduced 3 Hypoglycemia occurs in patients taking GLP-1 mimetics with SUs in non-fasting patients 4 TZD = thiazolidinedione; DPP-4 = dipeptidyl-peptidase 4; GLP-1 = glucagon-like peptide-1; SU = sulfonylurea. 1. Vasan et al. International J Diabetes Dev Countries. 2006;26: Devandra et al. Int J Clin Pract 2009;63: Norris et al. Diabetes Medicine. 2009;26: Bravis et al. Diabeteic Medicine 2010;27(suppl 1):130.
32 Section 6: Guidelines for Treating Patients with Diabetes During Ramadan
33 Fasting During The month of Ramadan For People With Diabetes: Medicine and Fiqh United at Last. SA Beshyah Ibnosina Journal of Medicine and Biomedical Sciences 2009, 1(2):58-60 This article is available from: Fasting during the lunar month of Ramadan is a religious obligation for all adult Moslems. Under certain circumstances, a few groups are exempt from fasting such as being sick as judged by an experienced doctor. Recent collaboration between the International Islamic Fiqh Academy and The Islamic Organization for Medical Sciences produced a comprehensive guidance based on extensive review of the evidence of possible risk to diabetic patients if they observe fasting.
34
35 The new guidance categorized people with diabetes into 4 groups according to their risk. Group 1 and 2 are exempted from fasting as they have risk from fasting. These included patients with poor glycemic control or with complications and serious coexisting illnesses in addition to type 1 patients and pregnant women with diabetes. Patients in groups 3 and 4 are those with moderate to low risk of harm from fasting. These are exemplified by uncomplicated patients with stable control on oral drugs not associated with excess risk of hypoglycemia. These groups of patients have no harm but may even benefit from fasting. Doctors and religious scholars have a joint responsibility to properly assess and advise patients to choose to fast or not to fast in line with these recommendations. Ibnosina Journal of Medicine and Biomedical Sciences 2009, 1(2):58-60
36 Recommendations by Risk Stratification Very High Risk and High Risk Advised not to fast as it can lead to worsened control and may result in severe hypoglycemia and diabetic ketoacidosis Moderate Risk Advised to see healthcare provider several months prior to fasting to adjust their diabetes treatment Low Risk Can fast without healthcare advice Hui et al. BMJ 2010;340:
37 Risk Stratification for Patients With Diabetes Who Fast During Ramadan: Very High Risk : Advised NOT to fast Classification of Risk Very High Risk Risk Factors Severe hypoglycemia within 3 months, recurrent hypoglycemia, and/or unawareness of hypoglycemia Poor glycemic control Ketoacidosis within 3 months Type 1 diabetes Acute illness Hyperosmolar hyperglycemic coma within 3 months Performing intense physical labor Pregnancy Al-Arouj et al. Diabetes Care 2010;33(8): Hui et al. BMJ 2010;340:
38 Risk Stratification for Patients With Diabetes Who Fast During Ramadan: High Risk: May fast with conditions Classification of Risk Risk Factors High Risk Moderate hyperglycemia (average blood glucose, mg/dl [8-16mmol/l] or HbA1c %) Comorbidities such as advanced macrovascular complications, renal disease on dialysis, cognitive dysfunction, or uncontrolled epilepsy Comorbid conditions that present additional risk factors Living alone and treated with insulin or sulfonylureas Elderly with ill health Al-Arouj et al. Diabetes Care 2010;33(8): Hui et al. BMJ 2010;340:
39 Risk Stratification for Patients With Diabetes Who Fast During Ramadan: Moderate or Low Risk: Can fast Classification of Risk Moderate Risk Low Risk Risk Factors Well-controlled diabetes treated with short-acting insulin secretagogues, sulfonylurea, insulin, or taking combination oral or oral plus insulin treatment Well-controlled diabetes treated with lifestyle therapy, metformin, DPP-4 inhibitors, thiazoladinediones, and/or incretin-based therapies in otherwise healthy individuals Al-Arouj et al. Diabetes Care 2010;33(8): Hui et al. BMJ 2010;340:
40 Medical Assessment 1 to 2 months before Ramadan Specific attention to overall well-being, control of glycemia, blood pressure, and lipids Appropriate blood studies should be ordered and evaluated Specific medical advice should be given to each individual, even if fasting against medical advice Necessary changes in diet and medication regimen should be made to patients who initiate fasting while on a stable and effective program Al-Arouj et al. Diabetes Care 2010;33(8):
41 Educating Patients Who Fast During Ramadan The role of structured education is well-established in the management of diabetes Structured instruction should be extended to Ramadan-focused diabetes education Education programs should ideally include: Awareness campaign for individuals with diabetes, healthcare professionals, and religious and community leaders Ramadan-focused structured education for healthcare professionals Ramadan-focused structured education for individuals with diabetes Al-Arouj et al. Diabetes Care 2010;33(8):
42 Ramadaan-focused Education Meal plan Appropriate exercise Blood glucose monitoring Finger prick or venesection does not break fast Recognition and management of hypoglycaemia and other acute complications Individualise treatment
43 Recommended Dietary Interventions During Ramadan Development of an individual dietary plan based on metabolic, nutritional, and lifestyle requirements 10 to 20% of caloric needs = protein 80 to 90% of caloric needs = fat and carbohydrates (<10% saturated fat) Distribution of fat and carbohydrates should be individualized based on nutrition and treatment objectives Benaji et al. Diabetes Res Clin Pract 2006;73(2):
44 Ramadan and Diabetes:DIET Split the daily calorie intake over two to three smaller meals during the non-fasting interval. Eat complex carbohydrates (e.g. oatmeal, bran,low GI rice) at Suhur (pre-dawn meal), and simple carbohydrates at Iftaar (sunset meal). Avoid foods with high sugar and fat content. Ensure adequate fluid intake during the nonfasting period.
45 METFORMIN The daily doses should be modified as follows: Two thirds after Iftaar (Eve.) One third at Suhur(Predawn) If the patient is taking modified-release metformin once daily, the dose should be taken after Iftaar rather than at Suhur
46 Management of Type 2 Diabetes in Patients Fasting During Ramadan: Oral Agents 1 Sulfonylureas Should be used with caution due to risk of hypoglycemia, although severe or fatal hypoglycemia is rare Glyburide or glibenclamide may be associated with higher risk of hypoglycemia than other second generation sulfonylureas e.g. gliclazide, glimepiride Studies have shown that repaglinide might be a safer alternative 2 1. Al-Arouj et al. Diabetes Care 2010;33(8): Sari et al. Endocr Res 2004;30(2):
47 SULPHONYLUREA S Reduce the morning dose if taking the drug twice daily. For example, change a twice-daily dose of gliclazide 80 mg to 80 mg at Iftaar(Eve.) and 40 mg at Suhur(Predawn) consider timing adjustment. For example, if taking a qd dose, switch it to Iftaar(Eve) Switch from glibenclamide to gliclazide, glimepiride or glinide to reduce risk of hypoglycaemia
48 OTHER ORAL AGENTS DPP-4 inhibiturs: No dose adjustment needed They are an alternative to sulphonylureas if the risk of hypoglycaemia is high. Thiazolidinediones: No adjustment necessary. Acarbose: To be taken at Suhur (AM)and Iftaar(PM) Oral short-acting betacell secretagogues The glinides (e.g. repaglinide) are short acting and can be taken twice daily, at Suhur and Iftaar
49 Diabetes and Fasting GLP-1 analogues No dose adjustment of GLP-1 analogue BUT if combined with sulphonylurea,reduce dose of the sulphonylurea
50 Management of Type 2 Diabetes in Patients Fasting During Ramadan: Insulin Treatment goals and complications similar to type 1 diabetes, except hypoglycemia risk is lower Option 1 Option 2 Option 3 Judicious use of intermediate- or long-acting insulin plus a short-acting insulin before predawn and sunset meals Use of long-acting or immediate-acting insulin once daily may provide adequate coverage in some patients. Dosage should be individualized Insulin pump: continuous insulin delivery with self-administered boluses at meals. Most will need to reduce basal infusion rate and increase bolus doses to cover predawn and sunset meals Hypoglycemia is still a risk, especially in patients who have required insulin therapy for a number of years or in whom insulin deficiency predominates, and in very elderly patients Most patients will require rapid- or short-acting insulin at both meals an d basal insulin at bedtime or if on premixed insulin ½ the usual eve dose AM and the usual AM dose PM Frequent glucose monitoring is required. Failure at pump or infusion site can cause severe deterioration of control over a few hours Al-Arouj et al. Diabetes Care 2010;33(8):
51 DIABETES AND FASTING Type 2 diabetics on Insulin 1. Basal/bolus Regime : ideal choice. Basal insulin at bedtime + rapid acting insulin at Suhur(AM) and Iftaar (PM) 2. Premixed insulin Give usual breakfast dose at Iftaar and 50 % of evening dose at Suhur N.B. Premixed 50/50 preferable at Iftaar for better post prandial control. 3. Bedtime Basal insulin + Oral agents Continue basal insulin but reduce the morning dose of oral agents
52 Fasting and Type 1 Diabetes Type 1 Diabetic patients should be advised NOT to fast However, some will insist on fasting. Such patients should be referred to a diabetologist who is well versed in the field of diabetes and Ramadaan
53 Recommended Changes to Treatment Regimens in Type 2 Diabetes Patients Fasting During Ramadan Before Ramadan Diet and exercise control Oral hypoglycemic agents Biguanide, metformin 500 mg TID During Ramadan Modify time and intensity of exercise. Ensure adequate fluid intake Ensure adequate fluid intake Metformin, 1000 mg at sunset meal, 500 mg at predawn meal TZDs, AGIs, or incretin-based therapies SUs QD SUs BID Insulin Premixed or intermediate-acting insulin BID No change needed Dose should be given before the sunset meal; adjust the dose based on glycemic control and risk of hypoglycemia Use half the usual morning dose at predawn meal and usual dose at sunset meal Ensure adequate fluid intake Consider switching to long-acting or intermediate insulin in evening and short or rapid-acting insulin with meals; or take usual dose at sunset meal and half usual dose at predawn meal AGI = α-glucosidase inhibitor; BID = twice daily; QD = once daily; SU = sulfonylurea; TID = thrice daily; TZD = thiazoladinedione. Al-Arouj et al. Diabetes Care 2010;33(8):
54
55 Fasting and Type 1 Diabetes : Recommendations 1.Control must be good Should be on basal/bolusinsulin regime, Short-acting Analogues preferred as bolus 2.Reduce total dose by 50 % 3.Give 60 % as basal 4.Give 40 % as bolus between the 2 meal 15 % at Suhur and 25 % at Iftaar 5.Insulin Pump(CSII) promising.
Managing diabetes in Ramadan
2nd EASD Postgraduate Course on Clinical Diabetes and its Complications Shiraz, Iran, 2-4 March 2017 Managing diabetes in Ramadan Fereidoun Azizi, M.D. Farhad Hosseinpanah, M.D. Research institute for
More informationDIABETES AND RAMADAN FASTING
DIABETES AND RAMADAN FASTING Dr. A. Nigam, M.B.B.S., M.D. (Medicine) Specialist Internal Medicine Al Zahrawi Hospital, Ras Al Khaimah, U.A.E. It is estimated that UAE s population currently stands at approximately
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationSitagliptin: A component of incretin based therapy. Rezvan Salehidoost, M.D., Endocrinologist
Sitagliptin: A component of incretin based therapy Rezvan Salehidoost, M.D., Endocrinologist Agenda Mode of Action Evidences for sitagliptine cardiovascular safety of sitagliptin Ramadan study Impact of
More informationDiabetes and Ramadan: Practical guidelines
Diabetes and Ramadan: Practical guidelines 1. Introduction Fasting during Ramadan is one of the five pillars of Islam and is obligatory for all healthy adult Muslims. The timing of Ramadan is based on
More informationTHE FACTS ABOUT FASTING DURING RAMADAN FOR PEOPLE WITH TYPE 2 DIABETES
THE FACTS ABOUT FASTING DURING RAMADAN FOR PEOPLE WITH TYPE 2 DIABETES 1 Introduction Ramadan; one of the five pillars of Islam Fasting is an important spiritual aspect of many religions. The Islamic month
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationDiabetes and Ramadan: A Challenge and an Opportunity?
Diabetes and Ramadan: A Challenge and an Opportunity? Dr Mohamed Hassanein Endocrinology Department, Dubai Hospital, UAE Chair of DAR International Alliance H Senior Lecturer, Cardiff University, UK mhassanein148@hotmail.com
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationبسم اهلل الرمحن الرحيم فمن شهد منكم الشهر
بسم اهلل الرمحن الرحيم فمن شهد منكم الشهر فليصمه Najat Buzaid Introduction Ramadan is a lunar-based month, and its duration varies between 29 and 30 days. The fasting hours vary from 10 hours in a temperature
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationGuidelines for managing diabetes in Ramadan
Guidelines for managing diabetes in Ramadan Sarah Ali 1, Melanie J Davies 2,3, Emer M Brady 3, Laura J Gray 4,, Kamlesh Khunti 2,3, Salem A Beshyah 5, Wasim Hanif 6 1. Department of Diabetes & Endocrinology,
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationThe effects of long term fasting in Ramadan on glucose regulation in type 2 Diabetes Mellitus
European Review for Medical and Pharmacological Sciences The effects of long term fasting in Ramadan on glucose regulation in type 2 Diabetes Mellitus C. KARATOPRAK, S. YOLBAS, M. CAKIRCA, A. CINAR, M.
More informationBetween health and faith - Managing diabetes during Ramadan. Ahmed Hussein Endocrine and Diabetes Registrar Blacktown-Mt Druitt Hospital
Between health and faith - Managing diabetes during Ramadan Ahmed Hussein Endocrine and Diabetes Registrar Blacktown-Mt Druitt Hospital Acknowledgment Dr Ibrahim Abu Muhammed Grand Mufti of Australia Professor
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More information第十五章. Diabetes Mellitus
Diabetes-1/9 第十五章 Diabetes Mellitus 陳曉蓮醫師 2/9 - Diabetes 羅東博愛醫院 Management of Diabetes mellitus A. DEFINITION OF DIABETES MELLITUS Diabetes Mellitus is characterized by chronic hyperglycemia with disturbances
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationGlycemic Control IU Health Diabetes Centers
Glycemic Control IU Health Diabetes Centers Central Nursing Orientation 3/10/2014 1 Objectives Identify laboratory results that diagnosis diabetes and reflect glycemic control Describe glycemic control
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationManagement of Diabetes in Ramadan Fasting
REVIEW ARTICLE Management of Diabetes in Ramadan Fasting Masoud Rahmanian 1*, Fateme Sadat Haghighi 2, Nasim Namiranian 3 1. Assistant Professor of Yazd Diabetes Research Center, Shahid Sadoughi University
More informationDiabetes mellitus. Treatment
Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationInformation for Patients
Information for Patients Guidance for Diabetic Persons having an OGD or Bronchoscopy This guidance is provided to assist with your preparation for your endoscopic procedure. If you feel unclear about how
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 VELMETIA 50 mg/850 mg, film-coated tablets B/56 (CIP code: 386 778-0) VELMETIA 50 mg/1 000 mg, film-coated
More informationDiabetes Management in New Brunswick Nursing Homes
Diabetes Management in New Brunswick Nursing Homes Prepared by Dr. Angela McGibbon March, 2016 As the population ages and with the rising incidence of diabetes, there are increasing numbers of people with
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationChapter 4. Risk Stratification of Individuals with Diabetes before Ramadan Monira Al-Arouj, Abdullah Ben-Nakhi & Mohamed Hassanein
Chapter 4. Risk Stratification of Individuals with Diabetes before Ramadan Monira Al-Arouj, Abdullah Ben-Nakhi & Mohamed Hassanein 41 4.1 Risks associated with fasting in people with diabetes During Ramadan,
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationTHE FACTS ABOUT FASTING DURING RAMADAN INFORMATION KIT FOR PEOPLE WITH TYPE 2 DIABETES
THE FACTS ABOUT FASTING DURING RAMADAN INFORMATION KIT FOR PEOPLE WITH TYPE 2 DIABETES INTRODUCTION This information kit is designed to provide you with facts and practical advice about fasting during
More informationFasting and Diabetes: An experience with safety of fasting in peoples with type II diabetes
: An experience with safety of fasting in peoples with type II diabetes Ahmed Bilal 1, Muhammad Sohail Anjum 2, Zaheer Ahmed 3 1 Chief Endocrinologist and Professor of Medicine, Head of Medical Unit II,
More informationCADTH Optimal use report
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Optimal use report Volume 3, Issue 1D July 2013 Optimal Use Recommendations
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationPERIOPERATIVE DIABETES GUIDELINE
PERIOPERATIVE DIABETES GUIDELINE This Guideline does not replace the need for the application of clinical judgment in respect to each individual patient. Background Diabetes mellitus is estimated to affect
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationBRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH
Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationOptimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationInpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy
Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of
More informationRamadan. Health Advice
Ramadan Health Advice Background The Holy month of Ramadan is the ninth month of the Islamic calendar in which Muslim adults observe the fast from dawn to sunset every year. Muslims observing the fast
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationDoes Technology helps adolescents with type 1 diabetes in fasting Ramadan?
Does Technology helps adolescents with type 1 diabetes in fasting Ramadan? Abdulmoein Al-Agha, FRCPCH Professor of Paediatric Endocrinology, King Abdulaziz University Hospital, http://aagha.kau.edu.sa
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationCanadian Diabetes Association 2013
Spring 2014 Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align to the guidelines? Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationInsulin Intensification: A Patient-Centered Approach
MARTIN J. ABRAHAMSON, MD Harvard Medical School, Boston, MA Insulin Intensification: A Patient-Centered Approach Dr Abrahamson is associate professor of medicine at Harvard Medical School and medical director
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationPharmacological Glycaemic Control in Type 2 Diabetes
Pharmacological Glycaemic Control in Type 2 Diabetes Aim(s) and Objective(s) This guideline aims to offer advice on the pharmacological management for those who require measures beyond diet and exercise
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationDiabetes education material. 1. Fasting plasma glucose (FPG) (No caloric intake for at least 8 hours)
How do I assess plasma glucose control? Diabetes education material There are four different ways to assess plasma glucose control: 1. Fasting plasma glucose (FPG) (No caloric intake for at least 8 hours)
More informationEndo 2 SLO Practice (online) Page 1 of 7
Endo 2 SLO Practice (online) Page 1 of 7 1. A long- acting insulin, like Lantus is for? A. When the next meal is within 30-60 minutes of the injection B. Over night use or for ½ of the day often combined
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationDPP-4 inhibitor. The new class drug for Diabetes
DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During
More informationSulfoniluree e glinidi: pro e contro
Sulfoniluree e glinidi: pro e contro Giorgio Sesti Università Magna Graecia di Catanzaro ITALY T2DM anti-hyperglycaemic therapy: general recommendations Diabetes Care 35:1364-1379, 2012; Diabetologia 55:1577-1596,
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationChoosing a Diabetes Strategy Where to Start and Where to Go
Choosing a Diabetes Strategy Where to Start and Where to Go Erin Keely, MD, FRCPC; and Sharon Brez, RN, BScN, MA(Ed), CDE As presented at the University of Ottawa's 52nd Annual Refresher Course for Family
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationThe Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines
The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationDiabetes Mellitus and Ramadan: Physiopathological, Clinical and Therapeutic Aspects
Cloud Publications International Journal of Advanced Nutritional and Health Science 2017, Volume 5, Issue 1, pp. 256-265 ISSN 2348-5140, Crossref: 10.23953/cloud.ijanhs.322 Review Article Diabetes Mellitus
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT Objectives u At conclusion of the presentation the participant will: 1. Discuss challenges to glycemic control unique in the older population
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationIn-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University
In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More information